These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 15459315)
1. Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. Lindén O N Engl J Med; 2004 Sep; 351(14):1466-7. PubMed ID: 15459315 [No Abstract] [Full Text] [Related]
2. Successful treatment with daclizumab of refractory anaplastic lymphoma. Costa V; Oliva T; Norton L Pediatr Blood Cancer; 2009 Dec; 53(6):1130-1. PubMed ID: 19598219 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800 [TBL] [Abstract][Full Text] [Related]
4. Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. Go A; Venugopal P; Loew J; Djordjevic D Clin Adv Hematol Oncol; 2006 Jun; 4(6):439-41. PubMed ID: 16981666 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. Herold M; Schnohr S; Bittrich H J Clin Oncol; 2001 Jul; 19(14):3439. PubMed ID: 11454895 [No Abstract] [Full Text] [Related]
6. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy. Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
9. Primary large B-cell lymphoma of the bone marrow. Hishizawa M; Okamoto K; Chonabayashi K; Kaneko H; Watanabe M; Tsudo M Br J Haematol; 2007 Feb; 136(3):351. PubMed ID: 17233843 [No Abstract] [Full Text] [Related]
10. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD; Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747 [TBL] [Abstract][Full Text] [Related]
12. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785 [TBL] [Abstract][Full Text] [Related]